Global Arthritis Monoclonal Antibodies 麻豆原创 Research Report 2024

Publication ID:

PB506248125

Publication Date:

June 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Arthritis Monoclonal Antibodies are a group of complex and effective biological agents used to treat arthritis and other immune-mediated inflammatory diseases
The global Arthritis Monoclonal Antibodies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Arthritis Monoclonal Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Arthritis Monoclonal Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Arthritis Monoclonal Antibodies in Rheumatoid Arthritis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Arthritis Monoclonal Antibodies include AbbVie Inc, F. Hoffmann-La Roche Ltd, Novartis, Johnson & Johnson(Janssen), Pfizer Inc, Mylan, Genentech, GSK and AstraZeneca PLC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Arthritis Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Arthritis Monoclonal Antibodies.
Report Scope
The Arthritis Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Arthritis Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Arthritis Monoclonal Antibodies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
AbbVie Inc
F. Hoffmann-La Roche Ltd
Novartis
Johnson & Johnson(Janssen)
Pfizer Inc
Mylan
Genentech
GSK
AstraZeneca PLC
Segment by Type
Remicade
Humira
Enbrel
Rituxan
Orencia
Actemra
Simponi
Cimzia
Segment by Application
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Fibromyalgia
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Arthritis Monoclonal Antibodies companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Arthritis Monoclonal Antibodies 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Remicade
1.2.3 Humira
1.2.4 Enbrel
1.2.5 Rituxan
1.2.6 Orencia
1.2.7 Actemra
1.2.8 Simponi
1.2.9 Cimzia
1.3 麻豆原创 by Application
1.3.1 Global Arthritis Monoclonal Antibodies 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Rheumatoid Arthritis
1.3.3 Osteoarthritis
1.3.4 Psoriatic Arthritis
1.3.5 Ankylosing Spondylitis
1.3.6 Fibromyalgia
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Arthritis Monoclonal Antibodies 麻豆原创 Perspective (2019-2030)
2.2 Arthritis Monoclonal Antibodies Growth Trends by Region
2.2.1 Global Arthritis Monoclonal Antibodies 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Arthritis Monoclonal Antibodies Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Arthritis Monoclonal Antibodies Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Arthritis Monoclonal Antibodies 麻豆原创 Dynamics
2.3.1 Arthritis Monoclonal Antibodies Industry Trends
2.3.2 Arthritis Monoclonal Antibodies 麻豆原创 Drivers
2.3.3 Arthritis Monoclonal Antibodies 麻豆原创 Challenges
2.3.4 Arthritis Monoclonal Antibodies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Arthritis Monoclonal Antibodies Players by Revenue
3.1.1 Global Top Arthritis Monoclonal Antibodies Players by Revenue (2019-2024)
3.1.2 Global Arthritis Monoclonal Antibodies Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Arthritis Monoclonal Antibodies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Arthritis Monoclonal Antibodies Revenue
3.4 Global Arthritis Monoclonal Antibodies 麻豆原创 Concentration Ratio
3.4.1 Global Arthritis Monoclonal Antibodies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Arthritis Monoclonal Antibodies Revenue in 2023
3.5 Arthritis Monoclonal Antibodies Key Players Head office and Area Served
3.6 Key Players Arthritis Monoclonal Antibodies Product Solution and Service
3.7 Date of Enter into Arthritis Monoclonal Antibodies 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Arthritis Monoclonal Antibodies Breakdown Data by Type
4.1 Global Arthritis Monoclonal Antibodies Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Arthritis Monoclonal Antibodies Forecasted 麻豆原创 Size by Type (2025-2030)
5 Arthritis Monoclonal Antibodies Breakdown Data by Application
5.1 Global Arthritis Monoclonal Antibodies Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Arthritis Monoclonal Antibodies Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Arthritis Monoclonal Antibodies 麻豆原创 Size (2019-2030)
6.2 North America Arthritis Monoclonal Antibodies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2019-2024)
6.4 North America Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Arthritis Monoclonal Antibodies 麻豆原创 Size (2019-2030)
7.2 Europe Arthritis Monoclonal Antibodies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2019-2024)
7.4 Europe Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Arthritis Monoclonal Antibodies 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Arthritis Monoclonal Antibodies 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Arthritis Monoclonal Antibodies 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Arthritis Monoclonal Antibodies 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Arthritis Monoclonal Antibodies 麻豆原创 Size (2019-2030)
9.2 Latin America Arthritis Monoclonal Antibodies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Arthritis Monoclonal Antibodies 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Arthritis Monoclonal Antibodies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Arthritis Monoclonal Antibodies 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc
11.1.1 AbbVie Inc Company Detail
11.1.2 AbbVie Inc Business Overview
11.1.3 AbbVie Inc Arthritis Monoclonal Antibodies Introduction
11.1.4 AbbVie Inc Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.1.5 AbbVie Inc Recent Development
11.2 F. Hoffmann-La Roche Ltd
11.2.1 F. Hoffmann-La Roche Ltd Company Detail
11.2.2 F. Hoffmann-La Roche Ltd Business Overview
11.2.3 F. Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Introduction
11.2.4 F. Hoffmann-La Roche Ltd Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.2.5 F. Hoffmann-La Roche Ltd Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Arthritis Monoclonal Antibodies Introduction
11.3.4 Novartis Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson(Janssen)
11.4.1 Johnson & Johnson(Janssen) Company Detail
11.4.2 Johnson & Johnson(Janssen) Business Overview
11.4.3 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Introduction
11.4.4 Johnson & Johnson(Janssen) Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.4.5 Johnson & Johnson(Janssen) Recent Development
11.5 Pfizer Inc
11.5.1 Pfizer Inc Company Detail
11.5.2 Pfizer Inc Business Overview
11.5.3 Pfizer Inc Arthritis Monoclonal Antibodies Introduction
11.5.4 Pfizer Inc Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.5.5 Pfizer Inc Recent Development
11.6 Mylan
11.6.1 Mylan Company Detail
11.6.2 Mylan Business Overview
11.6.3 Mylan Arthritis Monoclonal Antibodies Introduction
11.6.4 Mylan Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.6.5 Mylan Recent Development
11.7 Genentech
11.7.1 Genentech Company Detail
11.7.2 Genentech Business Overview
11.7.3 Genentech Arthritis Monoclonal Antibodies Introduction
11.7.4 Genentech Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.7.5 Genentech Recent Development
11.8 GSK
11.8.1 GSK Company Detail
11.8.2 GSK Business Overview
11.8.3 GSK Arthritis Monoclonal Antibodies Introduction
11.8.4 GSK Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.8.5 GSK Recent Development
11.9 AstraZeneca PLC
11.9.1 AstraZeneca PLC Company Detail
11.9.2 AstraZeneca PLC Business Overview
11.9.3 AstraZeneca PLC Arthritis Monoclonal Antibodies Introduction
11.9.4 AstraZeneca PLC Revenue in Arthritis Monoclonal Antibodies Business (2019-2024)
11.9.5 AstraZeneca PLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

AbbVie Inc
F. Hoffmann-La Roche Ltd
Novartis
Johnson & Johnson(Janssen)
Pfizer Inc
Mylan
Genentech
GSK
AstraZeneca PLC

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.